Skip to content

Localization of Nonpalpable Breast Lesions

A Randomized Study of Localization of Nonpalpable Breast Lesions - RSL vs WGL

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01901991
Enrollment
410
Registered
2013-07-17
Start date
2014-01-31
Completion date
2016-02-29
Last updated
2017-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Carcinoma in Situ

Keywords

Nonpalpable breast lesions, Breast Cancer and carcinoma in situ, Radioactive seed localization, Wire-guided localization, Randomized study

Brief summary

Each year the Danish mammography-screening programme identifies a large number of patients with small non-palpable breast cancers or precancerous lesions. The majority of these patients are suitable for breast conserving surgery (BCS). The object of BCS is to remove the suspicious lesion completely without removing excess healthy breast tissue. To obtain this accurate lesion localization is essential. Until today the standard procedure in Denmark has been wire guided localization (WGL). Although the method has been utilized for a number of years it has several disadvantages. Often inaccurate lesion localization leads to incomplete lesion removal (positive margin) and subsequently reoperation. It can postpone the additional systemic treatment, offered after the operation. Other disadvantages are poor cosmetic outcome and inconvenient planning for the patient and the departments involved. The wire needs to be placed on the day of the operation, which decreases the flexibility of the procedure. The purpose of this study is to test a new method named radioactive seed localization (RSL). The method uses a small titanium seed containing radioactive iodine. It will be placed in the centre of the lesion, and during the operation, the surgeon can locate it with a handheld gamma probe. The seed can be placed a few days in advance, which means a more flexible course of treatment. The method seems promising with regards to reoperation rates, but it needs further testing. Hypothesis: RSL is a more accurate method, for localization of nonpalpable breast lesions, than WGL. Using RSL obtains, to a great extent, adequate negative margins, resulting in a reduced number of re-operations. The study will be performed as a randomised clinical trial, where the two methods will be compared to each other. The trial will be performed at the department of breast surgery at Rigshospitalet and include patients with nonpalpable breast lesions. Besides reoperation rates, duration of the surgical procedure and the amount of removed breast tissue will be compared.

Interventions

PROCEDURERadioactive seed localization (RSL)

Localization of nonpalpable breast lesions with Radioactive seed localization

PROCEDUREWire-guided localization (WGL)

Localization of nonpalpable breast lesions with Wire-guided localization

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with nonpalpable breast lesions, carcinoma in situ or invasive carcinoma, where preoperative lesion localization is necessary. * All age groups, minimum 18 years

Exclusion criteria

* Patients with benign nonpalpable breast lesions. * Patients who are unable to comprehend the information. * Patients who are pregnant, breastfeeding or have children \< 3 years. * Patients who have lesions, which requires more than two wires or seeds for localization.

Design outcomes

Primary

MeasureTime frame
Re-operation rate due to positive microscopic margins detected at the final pathological evaluation.Re-operation within 3 months after the initial breast conserving surgery.

Secondary

MeasureTime frame
Amount of excised breast tissue in relation to tumour size.3 months.

Other

MeasureTime frame
Duration of the surgical procedure.3 months.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026